For the year ending 2025-12-31, CPIX had -$6,519,491 decrease in cash & cash equivalents over the period. $4,834,619 in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -2,864,711 |
| Depreciation and amortization expense | 4,145,201 |
| Amortization of operating lease right-of-use asset | 1,140,738 |
| Loss on co-commercialization investment | -13,220 |
| Disposal of assets | 0 |
| Stock-based compensation | 408,320 |
| Increase (decrease) in non-cash contingent consideration | 46,569 |
| Increase in cash surrender value of life insurance policies over premiums paid | 142,927 |
| Noncash interest expense | 23,185 |
| Life insurance proceeds | 0 |
| Accounts receivable | 5,243,314 |
| Inventories, net | -2,242,616 |
| Other current assets and other assets | 231,829 |
| Operating lease liabilities | -836,100 |
| Accounts payable and other current liabilities | 6,709,196 |
| Other long-term liabilities | -477,642 |
| Net cash provided by (used in) operating activities | 4,932,522 |
| Additions to property and equipment | 97,903 |
| Additions to intangible assets | 84,402 |
| Net investment in manufacturing | 2,477,192 |
| Other investment | 2,000,000 |
| Increase in cash surrender value of life insurance policies | 47,000 |
| Life insurance policy proceeds received | 0 |
| Net cash provided by (used in) investing activities | -4,706,497 |
| Borrowings on line of credit | 0 |
| Payments on line of credit | 10,035,437 |
| Proceeds from atm offering, net | -5,266,334 |
| Payments made in connection with repurchase of common shares | 263,478 |
| Cash settlement of contingent consideration | 1,712,935 |
| Net cash provided by (used in) financing activities | -6,745,516 |
| Net decrease in cash and cash equivalents | -6,519,491 |
| Cash and cash equivalents, beginning of year | 17,964,184 |
| Cash and cash equivalents, end of year | 11,444,693 |
CUMBERLAND PHARMACEUTICALS INC (CPIX)
CUMBERLAND PHARMACEUTICALS INC (CPIX)